AU2002231223A1 - Compositions and methods for treating hematologic malignancies and multiple drug resistance - Google Patents

Compositions and methods for treating hematologic malignancies and multiple drug resistance

Info

Publication number
AU2002231223A1
AU2002231223A1 AU2002231223A AU3122302A AU2002231223A1 AU 2002231223 A1 AU2002231223 A1 AU 2002231223A1 AU 2002231223 A AU2002231223 A AU 2002231223A AU 3122302 A AU3122302 A AU 3122302A AU 2002231223 A1 AU2002231223 A1 AU 2002231223A1
Authority
AU
Australia
Prior art keywords
compositions
methods
drug resistance
multiple drug
hematologic malignancies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002231223A
Inventor
Sean P Colgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2002231223A1 publication Critical patent/AU2002231223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU2002231223A 2000-10-26 2001-10-25 Compositions and methods for treating hematologic malignancies and multiple drug resistance Abandoned AU2002231223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24354200P 2000-10-26 2000-10-26
US60/243,542 2000-10-26
PCT/US2001/049856 WO2002034291A2 (en) 2000-10-26 2001-10-25 Compositions and methods for treating hematologic malignancies and multiple drug resistance

Publications (1)

Publication Number Publication Date
AU2002231223A1 true AU2002231223A1 (en) 2002-05-06

Family

ID=22919154

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231223A Abandoned AU2002231223A1 (en) 2000-10-26 2001-10-25 Compositions and methods for treating hematologic malignancies and multiple drug resistance

Country Status (3)

Country Link
US (1) US7105656B2 (en)
AU (1) AU2002231223A1 (en)
WO (1) WO2002034291A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
JP4546454B2 (en) * 2003-01-28 2010-09-15 レクサーン・コーポレイション Antisense oligonucleotide that suppresses HIF-1 expression
US7205283B2 (en) * 2003-01-31 2007-04-17 Rexahn Corporation Antisense oligonucleotides that inhibit expression of HIF-1
FR2860237B1 (en) 2003-09-30 2006-03-10 Centre Nat Rech Scient INTERACTION POLYPEPTIDE COMPRISING A HEPTAPEPTIDE PATTERN AND A CELL PENETRATION DOMAIN
EA014097B1 (en) 2004-11-09 2010-08-30 Сантарис Фарма А/С Potent lna oligonucleotides for modulating of hif-1a expression and use thereof
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
CN109224064A (en) 2009-12-04 2019-01-18 昂科免疫有限公司 The purposes of hypoxia inducible factor inhibitor
US20230212296A1 (en) * 2020-06-02 2023-07-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968735A (en) * 1992-11-12 1999-10-19 Max Delbruck-Centrum Fur Molekular Medizin Berlin Vector for the expression of therapy-relevant genes
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
CA2273185A1 (en) * 1996-11-05 1998-05-14 Board Of Regents, The University Of Texas System Compositions and uses for sentrin, a cell-death protecting protein
AU9110798A (en) 1997-08-21 1999-03-08 Quark Biotech, Inc. Hypoxia-regulated genes
US5985664A (en) * 1998-12-17 1999-11-16 Isis Pharmaceuticals, Inc. Antisense modulation of Sentrin expression
GB9911047D0 (en) 1999-05-12 1999-07-14 Isis Innovation Assay method and means
SE0002551D0 (en) * 2000-07-06 2000-07-06 Pharmacia & Upjohn Ab Screening methods

Also Published As

Publication number Publication date
US7105656B2 (en) 2006-09-12
WO2002034291A3 (en) 2003-05-30
WO2002034291A2 (en) 2002-05-02
US20050203036A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2002335647A1 (en) Methods and devices for electrosurgery
AU2001277754A1 (en) Proline derivatives and use thereof as drugs
AU2001294808A1 (en) Catecholamine pharmaceutical compositions and methods
AU8547001A (en) Composition and method for inhibiting platelet aggregation
AU2002230407A1 (en) Compounds and methods for treating multidrug resistance
AU2001280599A1 (en) Compounds and methods
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2002359126A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
HU0103078D0 (en) Pharmaceutical compositions and methods for treating cataracts
AU5565099A (en) Pharmaceutical compositions and methods for use
AU2002359123A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
AU2001243394A1 (en) Compounds and methods
AU2002231223A1 (en) Compositions and methods for treating hematologic malignancies and multiple drug resistance
AU2002249888A1 (en) Microbial blend compositions and methods for their use
IL154240A0 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
IL153487A0 (en) Pharmaceutical compositions and methods for use
AUPQ872300A0 (en) Compounds and methods
AU2001233932A1 (en) Method and composition
IL153897A0 (en) Pharmaceutical compositions and methods for use
AU2001278951A1 (en) Compounds and methods
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer